ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments
Authors:
- 1 October 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 21 (9) , 737-748
Abstract
Advances in chromosomally rearranged ALK positive non-small cell lung cancer have been dramatic in only the last few years. Survival times have improved dramatically due to the introduction of ever more efficacious ALK inhibitors. These improvements have been due largely to improvements in blood-brain barrier penetration and the breadth of ligand binding pocket mutations against which the drugs are effective. However, the advances maybe slow due to the frequency of cancers with compound resistance mutations are appearing, suggesting the need to develop multiple ALK inhibitors to target different compound mutations.Another research area that promises to provide further gains is the use of drug combinations, with an ALK inhibitor combined with a drug targeting a “second driver” to overcome resistance. In this review, the range of secondary targets for ALK+ lung cancer and the potential for their clinical success are reviewed.Keywords
This publication has 94 references indexed in Scilit:
- Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case reportBMC Research Notes, 2013
- Evolutionary dynamics of cancer in response to targeted combination therapyeLife, 2013
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cellsBritish Journal of Cancer, 2012
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK InhibitorsClinical Cancer Research, 2011
- Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis ScreenChemical Biology & Drug Design, 2011
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsCancer Research, 2011
- Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion OncogeneCancer Research, 2010
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008